Cysteamine (Oral) Products for Employer Plans
Customize your policy alerts
Sign up for Cigna Policy IP0046 alerts
Get alerted when Policy IP0046 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for oral cysteamine products (specifically Procysbi) for treatment of nephropathic cystinosis for employer plans administered by Cigna, including documentation and prescriber specialty requirements.
Added requirement that patient is > 1 year of age for Procysbi.
Updated genetic confirmation language to require 'genetic testing confirmed biallelic pathogenic or likely pathogenic variants in the CTNS gene.'
Added documentation requirements for diagnosis confirmation (genetic testing or elevated WBC cystine) and for prior trial/intolerance to Cystagon when required.
Coverage Criteria for Procysbi (Oral Cysteamine)
Initial Therapy (FDA-Approved Indication)
Procysbi is considered medically necessary when the following ALL of the following are met (approve for 1 year):
Diagnosis confirmation
- ONE of: i. Genetic testing confirmed biallelic pathogenic or likely pathogenic variants in the CTNS gene
- OR: ii. White blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory
Methods and reference ranges vary by laboratory; values from different assay methods may not be interchangeable.
Initial approval duration: 1 year
Procysbi (delayed‑release cysteamine) is considered not medically necessary for any indication other than treatment of nephropathic cystinosis. This exclusion includes, but is not limited to, any off‑label use outside the documented indication; the list of not‑covered uses may be updated as new evidence becomes available.
The concomitant use of Cystagon and Procysbi is not supported and is considered not medically necessary; there are no data available to support combined therapy with these agents.
Product Coding and Key Attributes
| Procysbi | Procysbi (cysteamine bitartrate delayed-release capsules, delayed release granules Horizon) |
Provider Actions, Prior Authorization, and Documentation Requirements
Prior authorization required for Procysbi
Prior authorization is required for Procysbi. Initial approvals are provided for 1 year and the medication must be prescribed by or in consultation with a nephrologist or a metabolic disease specialist.
- Initial approval duration: 1 year
- Prescription must be by or in consultation with a nephrologist or metabolic disease specialist
Preferred product (Cystagon) trial required for employer groups
For employer groups, Procysbi approval requires that the patient has tried Cystagon and, per the prescriber, had inadequate efficacy or significant intolerance to Cystagon; documentation of the trial/intolerance is required.
- Employer group criterion: trial of Cystagon with inadequate efficacy or significant intolerance
- Documentation of the trial/intolerance is required
Documentation required for diagnosis and prior product trial
Documentation is required to confirm diagnosis and to support any prior trial or intolerance to Cystagon. Acceptable documentation may include chart notes, laboratory tests, genetic test results, and prescription/claims records.
- Diagnosis confirmation: genetic testing showing biallelic pathogenic or likely pathogenic CTNS variants [documentation required]
- Or: elevated white blood cell cystine concentration above the reporting laboratory's upper limit of normal [documentation required]
- Documentation to support prior trial/intolerance to Cystagon (e.g., prescription records, chart notes)
Claims without covered diagnosis/procedure codes will be denied
Claims submitted for services that are not accompanied by covered diagnosis or procedure codes under this Coverage Policy will be denied as not covered.
- Use the most appropriate covered diagnosis and/or procedure codes when billing
- Claims without covered codes under this policy will be denied as not covered
Definitions
Background
Cystinosis is a rare autosomal recessive lysosomal storage disorder that results in accumulation of cystine and crystal deposition within lysosomes across multiple organs, leading to progressive renal and extra‑renal dysfunction. The nephropathic form is the indication for cysteamine therapy because cysteamine depletes intracellular cystine and can slow disease progression.
Diagnosis is confirmed by either measurement of elevated cystine in white blood cells (polymorphonuclear leukocytes) or by identification of pathogenic CTNS gene variants. Prompt initiation of cysteamine therapy after diagnosis is recommended to reduce cystine accumulation and ongoing organ damage.
Revision History and Policy Changes
Effective date entry noting no criteria changes on review (administrative) — listed in revision history but not material to clinical criteria and therefore excluded from events summarizing material clinical changes.
Added documentation requirements to support diagnosis confirmation and prior trial/intolerance to Cystagon (acceptable documentation includes chart notes, laboratory tests, genetic test results, and prescription records).
Added requirement that patient is > 1 year of age for Procysbi approval and clarified genetic confirmation language to require 'genetic testing confirmed biallelic pathogenic or likely pathogenic variants in the CTNS gene.'
Initial internal revision noting addition that patient must be > 1 year of age and specificity for genetic testing confirmation wording ('biallelic pathogenic or likely pathogenic variants in the CTNS gene').
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.